EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024

Pham Thi Lan, Thuy Thi Phan Nguyen, Vu Tuan Anh, Daniel Golparian, Nguyen Thi Thuy Van, Ismael Maatouk, Magnus Unemo, WHO EGASP-Viet Nam WGS study group

The Lancet Regional Health - Western Pacific · 2025-10 · 63 · 101709

DOI: 10.1016/j.lanwpc.2025.101709 ↗

Kurz gefasst

Leserbrief in der Zeitschrift The Lancet Regional Health - Western Pacific, 2025-10. Verfasst von Pham Thi Lan und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Hospital of Dermatology and Venereology and Hanoi Medical University, Hanoi, Viet Nam. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, Örebro Universitet.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global public health concern, and the last option for gonorrhoea treatment, ceftriaxone, is threatened.1 Most ceftriaxone-resistant strains have links to Asia.1,2 World Health Organization (WHO) has expanded and improved its global AMR surveillance, especially in Asia. The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) uses standardised and quality-assured protocols in sentinel countries worldwide and has also implemented whole-genome sequencing (WGS).

Autor:innen und Institutionen

  • National Hospital of Dermatology and Venereology and Hanoi Medical University, Hanoi, Viet Nam.
  • Ho Chi Minh City Hospital of Dermatology and Venereology, Ho Chi Minh City, Viet Nam.
  • Quy Hoa Central Leprosy and Dermatology Hospital, Quy Nhơn Nam, Gia Lai, Viet Nam.
  • WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), Örebro University, Örebro, Sweden.
  • WHO Country Office, Hanoi, Viet Nam.
  • Global HIV, Hepatitis and STI Programmes, WHO, Geneva, Switzerland.

Förderung

  • World Health Organization
  • Örebro Universitet

Zitieren

APA

Lan, P. T., Phan Nguyen, T. T., Anh, V. T., Golparian, D., Thuy Van, N. T., Maatouk, I., Unemo, M., & WHO EGASP-Viet Nam WGS study group (2025). The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024. The Lancet Regional Health - Western Pacific, 63, 101709. https://doi.org/10.1016/j.lanwpc.2025.101709

Vancouver

Lan PT, Phan Nguyen TT, Anh VT, Golparian D, Thuy Van NT, Maatouk I, et al. The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024. The Lancet Regional Health - Western Pacific. 2025;63:101709. doi:10.1016/j.lanwpc.2025.101709

BibTeX
@article{Lan2025,
  author = {Lan, Pham Thi and Phan Nguyen, Thuy Thi and Anh, Vu Tuan and Golparian, Daniel and Thuy Van, Nguyen Thi and Maatouk, Ismael and Unemo, Magnus and WHO EGASP-Viet Nam WGS study group, WHO EGASP-Viet Nam WGS study group},
  title = {The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024},
  journal = {The Lancet Regional Health - Western Pacific},
  year = {2025},
  volume = {63},
  pages = {101709},
  doi = {10.1016/j.lanwpc.2025.101709}
}
Kostenlos starten →